Altamira Financial Statements From 2010 to 2024
| CYTO Stock | USD 0.40 0.02 4.17% |
Gross Profit -2.2 M | Market Capitalization 1.6 M | Enterprise Value Revenue 64.9314 | Revenue 120.3 K | Earnings Share 1.82 |
Altamira Therapeutics Total Revenue |
|
Check Altamira Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Altamira Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.2 M, Interest Expense of 544.9 K or Selling General Administrative of 4 M, as well as many indicators such as Price To Sales Ratio of 12.62, Dividend Yield of 0.0 or PTB Ratio of 0.23. Altamira financial statements analysis is a perfect complement when working with Altamira Therapeutics Valuation or Volatility modules.
Altamira | Select Account or Indicator |
Altamira Therapeutics Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altamira Therapeutics Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altamira Therapeutics Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altamira Therapeutics Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altamira Fundamental Market Drivers
| Cash And Short Term Investments | 617.4 K |
Altamira Upcoming Events
| 21st of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
About Altamira Therapeutics Financial Statements
Altamira Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Altamira Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.6 M | 1.7 M | |
| Cost Of Revenue | 1.7 M | 1.4 M | |
| Stock Based Compensation To Revenue | 1.01 | 1.24 | |
| Sales General And Administrative To Revenue | 10.37 | 10.89 | |
| Research And Ddevelopement To Revenue | 57.95 | 60.85 | |
| Capex To Revenue | 6.31 | 6.63 | |
| Revenue Per Share | 7.72 | 7.33 | |
| Ebit Per Revenue | (98.33) | (93.42) |
Pair Trading with Altamira Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Altamira Stock
| 0.92 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.89 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Altamira Stock
| 0.88 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.74 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.58 | PHVS | Pharvaris BV | PairCorr |
| 0.5 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.45 | ESLAW | Estrella Immunopharma | PairCorr |
The ability to find closely correlated positions to Altamira Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altamira Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altamira Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altamira Therapeutics to buy it.
The correlation of Altamira Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altamira Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altamira Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altamira Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Altamira Therapeutics Correlation against competitors. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.